- Published on
Ophthalmology – Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among older adults, particularly in developed countries, and is the most common cause of legal blindness in individuals aged 65 years and older in the United States. It is broadly classified into two forms: non-exudative (“dry”) AMD, which accounts for approximately 90% of cases, and exudative (“wet”) AMD, which represents about 10% but is responsible for the majority of severe vision loss. Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity from AMD, characterized by abnormalities in the inner choroidal vasculature, including a branching network of dilated vessels that lead to serous leakage and hemorrhage. PCV is more commonly seen in Asian and African or African American populations, while it is less frequent in Caucasians.
The incidence and prevalence of AMD increase significantly with age. Early AMD rises from about 3.9% in individuals aged 43–54 years to over 20% in those older than 75 years, while late AMD has a 5-year incidence of approximately 0.9%. Overall prevalence of AMD in adults over 40 years is around 9.2%. PCV prevalence varies widely, ranging from 4% to 14%, and may be significantly higher in certain populations, such as Japanese patients diagnosed with AMD. Risk factors for AMD include advancing age, family history, Caucasian race, smoking, hypertension, hyperlipidemia, obesity, and female gender. In contrast, PCV is more strongly associated with ethnicity and age.
Genetic factors play an important role in AMD, with associations identified in genes such as complement factor H (CFH), LOC387715, and HTRA1, with certain variants significantly increasing disease risk. PCV shares some genetic associations, particularly involving LOC387715 and HTRA1. The pathophysiology of AMD is multifactorial and includes degeneration of the retinal pigment epithelium (RPE), accumulation of photoreceptor debris forming drusen, reduced choroidal circulation leading to ischemia, and genetic susceptibility. In the exudative form, abnormal choroidal neovascular membranes develop beneath the retina or RPE, causing leakage and hemorrhage. In PCV, abnormalities in the inner choroidal vasculature result in polyp-like dilations and vascular networks that leak or bleed beneath the RPE.
Patients with AMD or PCV may present with central visual disturbances such as blurring, distortion (metamorphopsia), central scotomas, or may be asymptomatic in early stages. On examination, non-exudative AMD is characterized by drusen, pigmentary changes in the RPE, and eventual retinal thinning or geographic atrophy. Exudative AMD may show subretinal or intraretinal fluid, hemorrhage, lipid exudates, pigment epithelial detachment, or retinal pigment epithelial tears. PCV should be suspected in patients with exudative maculopathy, particularly in non-Caucasian individuals, those with peripapillary lesions, or cases with minimal drusen in the fellow eye.
Diagnosis relies heavily on imaging. Optical coherence tomography (OCT) is essential for identifying fluid, retinal thickening, and monitoring disease progression. Fluorescein angiography is used to identify and characterize choroidal neovascularization in AMD. Indocyanine green angiography is particularly useful in PCV for visualizing the characteristic polypoidal vascular lesions and branching networks. These imaging modalities are also critical in guiding treatment decisions and monitoring response to therapy.
Management of AMD depends on the stage and type of disease. For exudative AMD, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab and ranibizumab are the mainstay of treatment and have significantly improved visual outcomes. Additional therapies may include photodynamic therapy, thermal laser for selected cases, intravitreal steroids, or combination regimens in refractory cases. For non-exudative AMD, there is no curative treatment, but progression may be slowed with lifestyle modification and nutritional supplementation using AREDS formulations, which include vitamins C and E, zinc, beta-carotene, and copper. Risk factor modification, including smoking cessation and control of cardiovascular risk factors, is essential.
Management of PCV differs somewhat, with photodynamic therapy often playing a central role, particularly for subfoveal lesions. Anti-VEGF therapy is also used but may be less effective compared to its role in AMD, and combination therapy with anti-VEGF agents and photodynamic therapy has shown promising results. Referral to a retinal specialist is essential for both AMD and PCV to ensure appropriate diagnosis and management.
Patients require ongoing monitoring, including regular ophthalmologic evaluations and use of home Amsler grid testing to detect changes in vision. Low vision support may be necessary for those with significant visual impairment. Prognosis varies, with many patients maintaining functional vision with treatment, although both AMD and PCV can lead to progressive central vision loss. Despite this, these conditions do not affect overall lifespan or systemic health.
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among older adults, particularly in developed countries, and is the most common cause of legal blindness in individuals aged 65 years and older in the United States. It is broadly classified into two forms: non-exudative (“dry”) AMD, which accounts for approximately 90% of cases, and exudative (“wet”) AMD, which represents about 10% but is responsible for the majority of severe vision loss. Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity from AMD, characterized by abnormalities in the inner choroidal vasculature, including a branching network of dilated vessels that lead to serous leakage and hemorrhage. PCV is more commonly seen in Asian and African or African American populations, while it is less frequent in Caucasians.
The incidence and prevalence of AMD increase significantly with age. Early AMD rises from about 3.9% in individuals aged 43–54 years to over 20% in those older than 75 years, while late AMD has a 5-year incidence of approximately 0.9%. Overall prevalence of AMD in adults over 40 years is around 9.2%. PCV prevalence varies widely, ranging from 4% to 14%, and may be significantly higher in certain populations, such as Japanese patients diagnosed with AMD. Risk factors for AMD include advancing age, family history, Caucasian race, smoking, hypertension, hyperlipidemia, obesity, and female gender. In contrast, PCV is more strongly associated with ethnicity and age.
Genetic factors play an important role in AMD, with associations identified in genes such as complement factor H (CFH), LOC387715, and HTRA1, with certain variants significantly increasing disease risk. PCV shares some genetic associations, particularly involving LOC387715 and HTRA1. The pathophysiology of AMD is multifactorial and includes degeneration of the retinal pigment epithelium (RPE), accumulation of photoreceptor debris forming drusen, reduced choroidal circulation leading to ischemia, and genetic susceptibility. In the exudative form, abnormal choroidal neovascular membranes develop beneath the retina or RPE, causing leakage and hemorrhage. In PCV, abnormalities in the inner choroidal vasculature result in polyp-like dilations and vascular networks that leak or bleed beneath the RPE.
Patients with AMD or PCV may present with central visual disturbances such as blurring, distortion (metamorphopsia), central scotomas, or may be asymptomatic in early stages. On examination, non-exudative AMD is characterized by drusen, pigmentary changes in the RPE, and eventual retinal thinning or geographic atrophy. Exudative AMD may show subretinal or intraretinal fluid, hemorrhage, lipid exudates, pigment epithelial detachment, or retinal pigment epithelial tears. PCV should be suspected in patients with exudative maculopathy, particularly in non-Caucasian individuals, those with peripapillary lesions, or cases with minimal drusen in the fellow eye.
Diagnosis relies heavily on imaging. Optical coherence tomography (OCT) is essential for identifying fluid, retinal thickening, and monitoring disease progression. Fluorescein angiography is used to identify and characterize choroidal neovascularization in AMD. Indocyanine green angiography is particularly useful in PCV for visualizing the characteristic polypoidal vascular lesions and branching networks. These imaging modalities are also critical in guiding treatment decisions and monitoring response to therapy.
Management of AMD depends on the stage and type of disease. For exudative AMD, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab and ranibizumab are the mainstay of treatment and have significantly improved visual outcomes. Additional therapies may include photodynamic therapy, thermal laser for selected cases, intravitreal steroids, or combination regimens in refractory cases. For non-exudative AMD, there is no curative treatment, but progression may be slowed with lifestyle modification and nutritional supplementation using AREDS formulations, which include vitamins C and E, zinc, beta-carotene, and copper. Risk factor modification, including smoking cessation and control of cardiovascular risk factors, is essential.
Management of PCV differs somewhat, with photodynamic therapy often playing a central role, particularly for subfoveal lesions. Anti-VEGF therapy is also used but may be less effective compared to its role in AMD, and combination therapy with anti-VEGF agents and photodynamic therapy has shown promising results. Referral to a retinal specialist is essential for both AMD and PCV to ensure appropriate diagnosis and management.
Patients require ongoing monitoring, including regular ophthalmologic evaluations and use of home Amsler grid testing to detect changes in vision. Low vision support may be necessary for those with significant visual impairment. Prognosis varies, with many patients maintaining functional vision with treatment, although both AMD and PCV can lead to progressive central vision loss. Despite this, these conditions do not affect overall lifespan or systemic health.
0 Comments
